Compass Therapeutics Investor Presentation Deck

Treatment-Emergent ≥ Grade 3 Adverse Events (>10% of patients) Phase 2 BTC study of CTX-009 plus paclitaxel Bevacizumab and paclitaxel label information Event Neutropenia Anemia Hypertension Thrombocytopenia 24 total Patients N (%) 20 (83.3%) COMPASS THERAPEUTICS 5 (20.8%) 4 (16.7%) 3 (12.5%) TEAE leading to discontinuation: confusion, embolism, pneumonia (grade 5), biliary fistula, large intestine perforation, blood creatinine increased, and blood urea nitrogen increased Event Neutropenia Hypertension Anemia Thrombocytopenia Bevacizumab (label) 5-18% Additional events: Gl perforation, wound healing complications, Proteinuria, hemorrhage Paclitaxel (label) 52% 16% 7% Additional events: Hypersensitivity reactions, infections, bleeding, neuropathy 21

View entire presentation